ACE, angiotensin I converting enzyme, 1636

N. diseases: 1082; N. variants: 82
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Though, ACE inhibition is adequate to reduce SBP, targeting NEP and APN along with ACE is beneficial in tackling hypertension and associated fibrosis of heart. 31715212 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE Insertion/Deletion (I/D) polymorphism of <i>ACE</i> has pronounced effects on development of metabolic diseases like diabetes, cardiovascular diseases (CVDs) and hypertension. 30641607 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE ACE inhibitors, fibrates and AGIs were associated with increased prevalence of cortical cataract in this Asian population, independent of the presence of hypertension, hyperlipidaemia and diabetes, respectively. 31272959 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The present study further investigated whether inhibition of angiotensin-converting enzyme (ACE) or tumor necrosis factor-α (TNF-α) blocks sensitization of ANG II hypertension in offspring of HFD dams. 31746626 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Albuminuria acts as a marker of progressive chronic kidney disease and as an indicator for initiation of hypertension treatment via modulation of the renin-angiotensin-aldosterone system with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors. 31793908 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Repetitive intravenous injection of SHR-EVs increased blood pressure and vascular ACE contents, and promoted vascular remodelling in both strains, while WKY-EVs reduced vascular ACE contents and attenuated hypertension and vascular remodelling in SHR. 31839907 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE We hypothesized that perindopril, an angiotensin-converting enzyme (ACE) inhibitor, indicated for the treatment of hypertension (Ceconi et al., in Cardiovasc Res 73:237-246, 2007), and which plays a role in preventing endothelial dysfunction, may help to prevent or reduce the severity of regorafenib-induced HFSR. 30535909 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE He also presented with hypertension and genetic testing revealed that she had the high blood pressure D variant of the ACE gene in a heterozygous state, which moderately predisposes to hypertension. 30804141 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE These results suggest that chronic exposure to inorganic mercury aggravates hypertension and produces more expressive changes in ACE activity and oxidative stress in SHRs. 30624528 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Low albumin was associated with increasing age, higher urea and C-reactive protein, lower sodium, hemoglobin, iron, less treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, reduced right ventricular function, and pulmonary hypertension. 30637771 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE Epidemiologic data suggest that inactivation of the peptidase angiotensin-converting enzyme in patients treated for hypertension increases the odds to develop CRPS. 30694931 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE Influence of angiotensin-converting enzyme inhibition on reversibility of alterations in arterial wall and cognitive performance associated with early hypertension: A follow-up study. 31441902 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The organic extract of B. amyloliquefaciens displayed significantly greater antioxidative properties (IC<sub>90</sub> < 1 mg/mL) and the activities showed considerable positive correlation (r<sup>2</sup> > 0.8, P < 0.05) with the inhibitory activities against angiotensin converting enzyme-I, pro-inflammatory cyclooxygenases and 5-lipoxygenase, dipeptidyl peptidase-4 and hydroxymethylglutaryl coenzyme A reductase, which were associated with hypertension, inflammation, diabetes, and hypercholesterolemia, respectively. 30406296 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Whether FGF23 is associated with increased HF risk in populations with hypertension and whether this association is weaker in the presence of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy is unknown. 30256890 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Current therapeutic approach to hypertension management involves the use of drugs that inhibit excessive activities of renin and angiotensin converting enzyme (ACE), the two main enzymes that control mammalian blood pressure. 31353494 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE In this study, the active peptides, angiotensin I-converting enzyme inhibitory peptides (MW of 959.46 and 1,141.29 Da), obtained from TCJ hydrolysate and identified by LC-MS/MS would be a beneficial ingredient for nutraceuticals and functional food against hypertension. 31608485 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension. 30518809 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE Chymase is a major angiotensin-converting enzyme (ACE)-independent angiotensin convertase, and its expression is upregulated in the maternal vascular endothelium in preeclampsia, a hypertensive disorder in human pregnancy. 30518985 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Patients with hypertension plus nonuse of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers potentiated kidney damage by metformin. 31163098 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Angiotensin-converting enzyme inhibitors and calcium channel blockers in combination are widely recommended in hypertension guidelines. 30919249 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Although these preliminary findings must be confirmed by further researches with larger sample size, we could observe that the integrative analysis of ACE and ACE2 can be an informative tool in hypertension understanding that needs to be explored in new studies. 31430320 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Angiotensin-converting enzyme (ACE) and dipeptidyl peptidase-IV (DPP-IV) play critical roles in the development of hypertension and type 2 diabetes, respectively. 30599943 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE The present study investigated whether angiotensin (Ang) II-elicited hypertensive response is sensitized in a model of PTSD and whether inhibition of angiotensin-converting enzyme (ACE) or tumor necrosis factor (TNF)-α prior to PTSD blocks this sensitization of Ang II hypertension. 31063551 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Logistic regression analysis showed that the independent risk factors for AKI in patients with AMI included: age (>60 years old) (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.02-1.05, P = 0.000), hypertension (OR 2.51, 95% CI 1.62-3.87, P = 0.000), chronic kidney disease (OR 3.52, 95% CI 2.01-6.16, P = 0.000), Killip class ≥3 (OR 5.22, 95% CI 3.07-8.87, P = 0.000), extensive anterior myocardial infarction (OR 3.02, 95% CI 1.85-4.93, P = 0.000), use of furosemide (OR 1.02, 95% CI 1.02-1.03, P = 0.000), non-use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (OR 1.58, 95% CI 1.04-2.40, P = 0.032). 31261199 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Consensus recommendations were that (i) there is evidence of harm associated with postoperative systolic arterial pressure <90 mm Hg; (ii) for patients with preoperative hypertension, the threshold at which harm occurs may be higher than a systolic arterial pressure of 90 mm Hg; (iii) there is insufficient evidence to precisely define the level of postoperative hypertension above which harm will occur; (iv) a greater frequency of postoperative blood pressure measurement is likely to identify risk of harm and clinical deterioration earlier; and (v) there is evidence of harm from withholding beta-blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors in the postoperative period. 30916008 2019